Document ID: FDA-2014-N-0189-6251
Agency: fda
Document Type: Supporting & Related Material
Title: 
Posted Date: 2014-06-17T04:00Z

Comment Info: =================

General Comment:Dear Mr. Zeller:

I am writing as an individual consumer to request an extension of the comment period for the Food and Drug Administration's ("FDA") Proposed Rule Deeming Tobacco Products to be Subject to the Federal Food, Drug, and Cosmetic Act, as amended by the Family Smoking and Prevention and Tobacco Control Act (the "Proposed Rule") published at 79 Fed. Reg. 23,142 and Federal Register No. 2014-09491. On behalf of myself, I am requesting that the comment period for the Proposed Rule be extended by the FDA for an additional 105 days from its current 75-day period to 180 days.

The Proposed Rule raises a number of significant issues and questions that are important and relevant to me as a consumer of products that are proposed for regulation under the Proposed Rule. The Proposed Rule asks countless questions I might want to respond to. I would like to provide my thoughts and comments on many of these issues, but my time to devote to researching and providing thoughtful, relevant comments on these important questions is limited. I have already spent many hours researching and dissecting these issues, but as this will be my only chance to voice my opinions, I would like to be as thorough as possible. I do not think it is at all unreasonable to allow myself and other interested parties a mere six months to comment on the Proposed Rule. 

I feel very strongly about e-cigarettes as an alternative to combustible cigarettes. Quite simply, I firmly believe that they have saved my life and the lives of several of my family members and friends, not to mention thousands of others and potentially millions of future ex-smokers. I wish to provide you with my own personal story as well as science- and evidence-based responses to fully and accurately address your questions and concerns. I realize that the FDA has the authority under 21 CFR 10.40 to extend this time frame and that the FDA has exercised this authority on numerous occasions in the past. I would therefore ask that you do so here so that all stakeholders have the opportunity to provide their comments on this proposed regulation.

I appreciate your consideration of my request and am happy to discuss this issue with you further.

Most sincerely,

Aaron Miller